Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, Korea.
Retina. 2010 Jun;30(6):865-73. doi: 10.1097/IAE.0b013e3181c969e9.
The purpose of this study was to evaluate the results of vitrectomy in patients with vitreous hemorrhage associated with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
A retrospective review was conducted of consecutive cases of patients undergoing pars plana vitrectomy for nonclearing vitreous hemorrhage associated with neovascular AMD or PCV.
Twenty-four eyes of 23 patients were included. The mean length of time from the onset of vitreous hemorrhage to operation was 4.3 months. Twelve eyes had AMD, and 12 eyes of 11 patients had PCV. Additional treatments for active choroidal neovascularization or PCV were required in 12 eyes during follow-up. The mean visual acuity improved significantly from a logarithm of the minimum angle of resolution of 2.79 +/- 0.85 before operation to 1.61 +/- 0.98 at 2 months after operation (P < 0.001). Visual acuity was >or=20/200 in 9 eyes (37.5%) at 2 months after operation; 1 eye was in the AMD group, and the other eyes were in the PCV group. Improvement was more frequently observed in the PCV group (P = 0.005).
In this series, the functional outcomes of vitrectomy for vitreous hemorrhage associated with AMD were inferior to outcomes of the PCV group. Vitrectomy is beneficial for improving visual function in select cases of breakthrough vitreous hemorrhage.
本研究旨在评估玻璃体切割术治疗与年龄相关性黄斑变性（AMD）和息肉状脉络膜血管病变（PCV）相关的玻璃体积血的疗效。
对接受经睫状体平坦部玻璃体切割术治疗非吸收性玻璃体积血伴新生血管性 AMD 或 PCV 的连续病例进行回顾性分析。
共纳入 23 例患者的 24 只眼。从玻璃体积血发病到手术的平均时间为 4.3 个月。12 只眼为 AMD，11 例患者的 12 只眼为 PCV。在随访期间，12 只眼需要进行针对活跃性脉络膜新生血管或 PCV 的额外治疗。术后 2 个月，视力从术前最佳矫正视力的对数（LogMAR）2.79 ± 0.85 显著提高到 1.61 ± 0.98（P<0.001）。术后 2 个月，视力≥20/200 的眼有 9 只（37.5%）；其中 1 只为 AMD 组，其余均为 PCV 组。PCV 组的改善更为常见（P=0.005）。
在本系列中，与 PCV 组相比，玻璃体切割术治疗 AMD 相关玻璃体积血的功能预后较差。玻璃体切割术有利于改善特定情况下玻璃体积血的视力功能。
